The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2


We know it as the least expensive way to treat head lice.  Trials start in 30 days but I would think people will start using it off-label.   I would if I had Covid-19.   Vets use it for ticks.  Also skin lotion.  Merck makes it and gives away million of doses for treating ‘river blindness’.
Newsweek –
“Australian researchers have published a study showing a drug commonly used to treat parasite infections can also kill coronavirus in a laboratory setting in under 48 hours.

Researchers at Monash University in Melbourne, Australia have discovered that the antiparasitic drug Ivermectin can inhibit replication of SARS-CoV-2, the virus the causes COVID-19, according to a study published Friday in the journal Antiviral Research.

“Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective—that’s the next step,” said the study’s leader Dr. Kylie Wagstaff in a statement.

“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” she added.”

From Wikipedia: Ivermectin

Cost

The wholesale cost in the developing world is about US$0.12 for a course of treatment as of 2014.[10] This is down from an initial cost of US$6 proposed by Merck in 1987.[59] The company however has donated 100s of millions of courses of treatments since 1988 in more than 30 countries.[59] Between 1995 and 2010 the program using donated ivermectin to prevent river blindness is estimated to have prevented 7 million years of disability well costing US$257 million.[60]In the United States a course of treatment with pills costs about US$25–50 for a typical adult.[11] As of 2019 ivermectin tablets were the least expensive treatment option for lice in children at about US$10.[61] The hair lotion, however, is about US$300 for a course of treatment.[61] 

Pre-published research paper

https://reader.elsevier.com/reader/sd/pii/S0166354220302011?token=D47E703418F8AD03B234955F3A3A8A171369C0C3AC0DECF4FE281561832FAACEC4BC6572602DA96EA74CCB6E1CF53273

Al